Metagenomi (MGX) CFO Pamela Wapnick Sells 1,581 Shares

What Happened Pamela Wapnick, Chief Financial Officer of Metagenomi Therapeutics, sold 1,581 shares of common stock on 2026-03-05 at $1.60 per share, generating approximately $2,530 in proceeds. According to the filing, this sale was an automatic disposition to satisfy tax-withholding obligations on restricted stock units that vested and was not a volitional market trade by the reporting person.

Key Details

• Transaction date: 2026-03-05; Price: $1.60 per share; Shares sold: 1,581; Proceeds ≈ $2,530.
• Filing date: 2026-03-09 (filed within the Form 4 reporting window — timely).
• Reason/footnote: Shares were automatically sold to satisfy tax withholding for RSUs granted on 2024-04-01 (Footnote F1); not a discretionary sale.
• Shares owned after the transaction: not specified in the provided filing extract.

Context Automatic sales to cover tax withholding on vesting awards are common and generally not interpreted as a directional signal about an insider’s view of the stock. This was not a purchase or exercise; it was a withholding-related sale of vested RSU shares.